Proposed Tobacco Pollution Tax to Fund Smoking Control Projects

Apr.02.2025
Proposed Tobacco Pollution Tax to Fund Smoking Control Projects
UK Parliament proposes "polluter pays" tax on tobacco companies to raise £700 million for anti-smoking projects.

Key points:

  • A UK parliamentary group has proposed imposing a "polluter pays" tax on tobacco companies to raise £700 million to fund smoking cessation projects.
  • The Tobacco and Vapes Bill will gradually phase out tobacco sales and ban e-cigarette advertising.
  • This measure aims to reduce the number of smokers and eliminate the social and health burdens caused by smoking.

According to The Independent, on April 1st, a cross-party parliamentary group in the UK has proposed imposing a "polluter pays" tax on tobacco companies to fund projects aimed at reducing smoking rates.

 

The All-Party Parliamentary Group on Smoking and Health (APPG) has pointed out that despite the UK parliament passing "world-leading" smoking bans, there are still more measures that can be implemented to help the millions of people addicted to smoking. With 6 million smokers in the UK, the task of controlling smoking is not yet complete.

 

A new report released by a group of legislators proposes a series of recommendations, including:

 

  • The tobacco industry is being forced to pay a "polluter pays" tax to raise £700 million in funding for projects aimed at reducing smoking rates and narrowing the gap in life expectancy. 
  • Tobacco companies are required to disclose sales data to support national smoking control strategies. 
  • The government is encouraged to make tobacco less economically accessible to encourage more people to quit smoking.
  •  Health warnings should be added to cigarette packaging to raise public awareness of health risks. 
  • The government should set a target to reduce the number of smokers by 2 million by the summer of 2029 and achieve smoke-free status in the UK within 20 years. 
  • Ministers should use the The Tobacco and Vapes Bill to close loopholes allowing cigar lounges to continue operating. 
  • The government should "reduce barriers to access to smoking cessation aids" while also reducing the number of young people using e-cigarettes.

 

If the "The Tobacco and Vapes Bill" is passed, individuals born after January 1, 2009 will be prohibited from purchasing tobacco products, gradually phasing out tobacco sales. The act also includes a complete ban on e-cigarette advertising and sponsorship, as well as regulations stating that displays in places such as cinemas and shop windows must adhere to tobacco restrictions.

 

Furthermore, starting in June 2025, disposable e-cigarettes will be banned.

 

APPG co-chair and Labour MP Mary Foy stated,

 

"The UK is set to introduce world-leading new laws that will protect future generations from the enormous harms of smoking, but we cannot ignore the millions of people still trapped by addiction."

 

"The only people who benefit from smoking is the tobacco industry who generate huge profits from peddling misery and illness."

 

"It’s time for them to pay for the damage they cause."

 

A spokesperson for the UK Department of Health and Social Care stated that,

 

"The government is delivering the world leading Tobacco and Vapes Bill, creating the first smoke-free generation and ending the cycle of addiction and disadvantage."

 

"To clamp down on youth vaping, the Bill will ban vape advertising and sponsorship, and provide powers to regulate flavours and packaging, and how and where they are displayed in shops."

 

"We’re supporting current smokers to quit by investing an additional £70 million for local Stop Smoking Services, extending our Swap to Stop and National Smoke-Free Pregnancy Incentive schemes and working to ensuring all NHS hospitals offer ‘opt-out’ smoking cessation services."

 

We welcome news tips, article submissions, interview requests, or comments on this piece.

Please contact us at info@2firsts.com, or reach out to Alan Zhao, CEO of 2Firsts, on LinkedIn


Notice

1.  This article is intended solely for professional research purposes related to industry, technology, and policy. Any references to brands or products are made purely for objective description and do not constitute any form of endorsement, recommendation, or promotion by 2Firsts.

2.  The use of nicotine-containing products — including, but not limited to, cigarettes, e-cigarettes, nicotine pouchand heated tobacco products — carries significant health risks. Users are responsible for complying with all applicable laws and regulations in their respective jurisdictions.

3.  This article is not intended to serve as the basis for any investment decisions or financial advice. 2Firsts assumes no direct or indirect liability for any inaccuracies or errors in the content.

4.  Access to this article is strictly prohibited for individuals below the legal age in their jurisdiction.

 

Copyright

 

This article is either an original work created by 2Firsts or a reproduction from third-party sources with proper attribution. All copyrights and usage rights belong to 2Firsts or the original content provider. Unauthorized reproduction, distribution, or any other form of unauthorized use by any individual or organization is strictly prohibited. Violators will be held legally accountable.

For copyright-related inquiries, please contact: info@2firsts.com

 

AI Assistance Disclaimer

 

This article may have been enhanced using AI tools to improve translation and editorial efficiency. However, due to technical limitations, inaccuracies may occur. Readers are encouraged to refer to the cited sources for the most accurate information.

We welcome any corrections or feedback. Please contact us at: info@2firsts.com

U.S. Ninth Circuit Upholds FDA Denial of MH Global’s Flavored Vape PMTA Applications
U.S. Ninth Circuit Upholds FDA Denial of MH Global’s Flavored Vape PMTA Applications
The U.S. Court of Appeals for the Ninth Circuit upheld the FDA’s denial of MH Global LLC’s applications to market flavored electronic nicotine delivery systems (ENDS). The court ruled that FDA’s comparative-efficacy framework, which requires applicants to show that flavored products provide greater cessation or switching benefits than tobacco-flavored alternatives, is consistent with the Tobacco Control Act’s “appropriate for the protection of the public health” standard. The court also found that FDA was not required to establish the framework through notice-and-comment rulemaking.
Aug.26
Product | JT Launches Ploom AURA Glacier White in Japan, Expanding the Device Ecosystem Through Color and Accessories
Product | JT Launches Ploom AURA Glacier White in Japan, Expanding the Device Ecosystem Through Color and Accessories
Japan Tobacco Inc. (JT) has introduced the Ploom AURA Glacier White heated tobacco device in Japan, adding a new color option to the existing Ploom AURA lineup. The device maintains the existing SMART HEATFLOW technology and HEAT SELECT SYSTEM with four heating modes, while expanding the ecosystem through new accessories including front panels, back covers, a car holder and wireless charging covers. The product entered pre-sale in Japan on June 30, 2026, followed by broader retail availability from July 7.
Aug.03
China’s Jiangsu Tobacco Monopoly Bureau and Drug Regulator Target Illegal Vape Sales Disguised as Medical Devices, Define Six Violations
China’s Jiangsu Tobacco Monopoly Bureau and Drug Regulator Target Illegal Vape Sales Disguised as Medical Devices, Define Six Violations
China’s Jiangsu Tobacco Monopoly Bureau and Jiangsu Provincial Medical Products Administration have issued a joint notice targeting illegal production and sales of vape products disguised as medical devices. The notice identifies six categories of violations, including obtaining medical licenses through false materials, misusing medical device credentials, expanding production beyond approved scopes, and using medical device-related online platforms to promote or sell vape products. The action is based on China’s tobacco and medical device regulations and aims to strengthen vape oversight and consumer protection.
Aug.04
PMI Expands U.S. ZYN Portfolio With New 1.5 mg and 8 mg Strengths, Moves Toward a Unified 20-Pouch-Per-Can Format
PMI Expands U.S. ZYN Portfolio With New 1.5 mg and 8 mg Strengths, Moves Toward a Unified 20-Pouch-Per-Can Format
Philip Morris International is expanding its U.S. ZYN nicotine pouch portfolio with new 1.5 mg and 8 mg strengths and plans to move its core 3 mg and 6 mg dry-pouch products from 15 to 20 pouches per can in the fourth quarter of 2026. ZYN ULTRA is also commercially available, with FDA authorization covering 10 products at 9 mg and one 11 mg Smooth product. PMI U.S. lists the new 1.5 mg and 8 mg strengths as commercially available, but as of September 10 they do not appear on the FDA’s public authorization list. Public materials do not identify which PMTA submissions cover the two new strengths or their current review status.
Sep.11
STIIIZY Redesign Fails to Escape PAX Labs Patent Import Ban as Section 337 Case Also Involves China ALD
STIIIZY Redesign Fails to Escape PAX Labs Patent Import Ban as Section 337 Case Also Involves China ALD
U.S. Customs and Border Protection ruled that STIIIZY had not shown that the redesigned cannabis-vape products covered by its latest request fall outside an ITC limited exclusion order tied to PAX Labs patents. CBP accepted some of STIIIZY’s claim-construction and non-infringement arguments, but the company did not address two additional claims in the same patent. Earlier STIIIZY redesigned cartridges and certain associated components imported with them had received separate CBP clearance.
Sep.16
FDA Authorizes Four More Nicotine Pouches as Review Pilot Expands Beyond Initial Decisions
FDA Authorizes Four More Nicotine Pouches as Review Pilot Expands Beyond Initial Decisions
The FDA has authorized four additional on! nicotine pouches, bringing the U.S. total to 30. The decision marks another outcome of the agency’s nicotine pouch review pilot, whose communication and review practices are now being applied more broadly across the category. It also extends Helix’s authorized portfolio from on! PLUS to the earlier on! line. Yet all FDA-authorized nicotine pouches still come from subsidiaries of PMI or Altria, underscoring how concentrated U.S. regulatory access remains.
Aug.05